A b s t r a c t
Antibodies are currently the only commercially available and clinically validated probes for cell immunophenotyping studies and disease diagnosis. 1 However, the production of antibodies is a complicated process that includes animal handling, cell line maintenance, and protein purification. Thus, in the past years, researchers have searched for other ligand molecules that are less costly to produce and easier to handle. Short, single-stranded oligonucleotides (usually 30-50 bases) known as aptamers have emerged as a new class of small molecule ligands. 2, 3 By using the systematic evolution of ligands by exponential (also called SELEX) amplification technique, researchers have discovered a variety of RNA-or DNA-based aptamers that can specifically bind to their target molecules with high affinity at picomolar to nanomolar levels. [4] [5] [6] [7] [8] [9] As specific ligands, aptamers can bind to a broad array of targets, including ions, toxins, drugs, low-molecular-weight ligands, peptides, proteins, and cells. An RNA-based aptamer has been reported to specifically bind to recombinant human CD4 antigen. 10 However, the clinical value of this aptamer and its potential use for disease diagnosis have not been fully investigated. In this study, we synthesized the CD4 aptamer using the reported sequences and investigated its potential value in multicolored cell phenotyping of patient specimens.
Materials and Methods

Reagents
All antibodies were purchased from BD Biosciences, San Jose, CA. These antibodies included allophycocyanin (APC)-cyanine (Cy)7-and fluorescein isothiocyanate Upon completion of this activity you will be able to:
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(FITC)-conjugated CD4 antibody (clones SK3 and RPA-T4, respectively), FITC-and phycoerythrin (PE)-conjugated CD45 antibody (clones 2D1 and HI30, respectively), PE-conjugated CD3 antibody (clone SK7), and peridinin chlorophyll protein (PerCP)-conjugated CD8 antibody (clone SK1). All antibodies were used at a dilution of 1:20. For cell nuclear stain, 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) was purchased from Sigma, St Louis, MO. The RNA aptamer (41-mer) was synthesized according to the reported sequence 10 : 5'-AAGUGACGUCCUGAUC-GAUUGUGCAUUCGGUGUGACGAUCU-3' (Integrated DNA Technologies, Coralville, IA). The sequence was slightly modified so that 2 adenosine residues were present at the 5' end for Cy5 conjugation (for tracking purposes). In addition, ordinary nucleic acids were used for RNA synthesis instead of 2'-F modified nucleic acids. 10 After high-performance liquid chromatography purification, the synthetic aptamer probes were stored in nuclease-free water at -20°C until further use. The predicted 2-dimensional structure of the synthetic CD4 aptamer was generated using RNA structure software, version 4.6 (Mathews Lab Software, University of Rochester Medical Center, Rochester, NY) ❚Figure 1A❚.
Cell Culture and Specimen Preparation
The T-cell leukemia cell line (Jurkat), myeloma cell line (RPMI 8226), and Burkitt lymphoma cell line (Ramos) were purchased from American Type Culture Collection (ATCC, Manassas, VA). The anaplastic large cell lymphoma cell lines, Karpas 299 cells and SUDHL-1, were from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Patients' specimens were handled according to an institutional review board-approved protocol. Bone marrow aspirates from 5 healthy donors were collected in the presence of anticoagulant, and nucleated cells were prepared as described previously. 11 Cells from 5 patients' pleural fluid samples were collected by centrifugation and washed once in phosphatebuffered saline (PBS). Lymph node tissues from 5 patients without lymphoma were subjected to vigorous cutting and repeated pipetting to generate a cell suspension in cold PBS. The cell solution was then filtered through a 100-μm strainer (BD Biosciences, San Jose, CA) to prepare a single-cell suspension.
Analysis of Cell Binding and Stability of the CD4 Aptamer
For cell-binding assays, cultured cells (5 × 10 5 per assay) were incubated at room temperature for 20 minutes with the CD4 aptamer in 100 μL of cell-binding buffer (bovine serum albumin [BSA] and magnesium chloride [Sigma-Aldrich, St Louis, MO] in PBS) and washed once with 1 mL cell-binding buffer. Binding of the CD4 aptamer to cells was then detected by flow cytometry (LSR-II, BD Biosciences) and analyzed by using FlowJo (version 7.0) software (Tree Star, Ashland, OR). Optimal cell-binding conditions were determined by varying concentrations of BSA and magnesium chloride in the cell-binding buffer (data not shown). The optimal cellbinding buffer (PBS, pH 7.4) was found to contain 1 mmol/L magnesium chloride and 2 mg/mL BSA. This buffer was used throughout the study. Cell-binding assays were also performed using varying concentrations of CD4 aptamer in the presence of CD4-expressing cells (Jurkat and Karpas 299) and CD4-cells (SUDHL-1, Ramos, and RPMI 8226). Dose-response and time-course assays revealed that the optimal final concentration of CD4 aptamer probes for cell staining (data not shown) was 0.3 nmol/L. This concentration was used throughout the study.
The stability of the CD4 aptamer under clinical conditions was tested by diluting the probe to a concentration of 30 nmol/L in cell-binding buffer, storing the diluted probe at room temperature for varying times, and then testing the probe in cell-binding assays (the final probe concentration in these assays was 0.3 nmol/L). For biostability evaluations, cell-binding assays were conducted by incubating 0.3 nmol/L of CD4 aptamer probe with cells at room temperature for 20 minutes. The mixtures were then stored at 4°C for varying times, and the remaining signal of the cell-bound CD4 aptamer was quantified by flow cytometry.
Cell Staining and Fluorescence Microscopy
CD4-SUDHL-1 cells were pretreated with 1 μg/mL DAPI for nuclear staining and mixed with CD4-expressing Karpas 299 cells at a 1:1 ratio. The cell mixtures were then incubated at room temperature for 20 minutes with 0.3 nmol/L Cy5-conjugated CD4 aptamer probe and 1:20-diluted FITC-conjugated anti-CD4 antibody. Cells were washed once with PBS, mounted on slides, and examined under a fluorescent microscope (Olympus IX71, Leeds Instruments, Irving, TX).
Multicolored Phenotyping Using CD4 Aptamer Probe and Antibodies
Cultured cells and cells from patients' specimens were incubated with multiple probes simultaneously. These probes included CD4 aptamer (0.3 nmol/L), CD3 antibody, CD4 antibody, CD8 antibody, and CD45 antibody. Cell phenotyping was then performed using multicolored flow cytometry.
Results
Specific Cell Binding by the CD4 Aptamer Probe
First, specific cell binding by the CD4 aptamer was investigated using CD4-expressing cells (ie, Karpas 299 and Jurkat cells) and CD4-cells (ie, SUDHL-1, Ramos, and RPMI 8226 and CD4 antibody had nearly identical binding specificity to CD4-expressing and CD4-cells ❚Figure 1B❚.
Next, the biostability of the CD4 aptamer was tested. Cell-binding assays showed that the CD4 aptamer retained cells). As a positive control, a subset of cells was incubated with CD4 antibody, the only clinically validated probe for immunophenotyping cellular CD4 expression. Flow cytometric analysis of cell binding revealed that the CD4 aptamer approximately 65% of its cell-binding capacity after 24 hours of storage at room temperature ❚Figure 1C❚. In addition, stability evaluations showed that, following completion of cell-binding reactions, a 24-hour storage of cell-bound CD4 aptamer at 4°C resulted in only a mild decrease (23% reduction) in the fluorescent signal of the aptamer ❚Figure 1D❚.
To further characterize CD4 aptamer cell binding, we compared the cell-binding patterns of CD4 aptamer and CD4 antibody using fluorescence microscopy. In these experiments, a mixture of CD4-expressing cells (Karpas 299) and DAPI-stained, CD4-cells (SUDHL-1) were simultaneously incubated with the CD4 aptamer and CD4 antibody. We found that the CD4 aptamer (red fluorescent signal) ❚Image 1B❚ labeled Karpas 299 cells with a pattern identical to that for CD4 antibody (green signal) ❚Image 1C❚, as can be seen in the merged image (yellow) ❚Image 1E❚. In contrast, neither 
Multicolored Cell Phenotyping Using a Combination of CD4 Aptamer Probe and Antibodies
One of the advantages of modern flow cytometry is that it allows detection of multiple biomarkers on the same cells simultaneously. We tested whether the CD4 aptamer could be used in combination with antibodies for CD3 (conjugated with PE), CD8 (PerCP), and CD45 (FITC) for multicolored phenotyping of cultured cells. A subset of cells was labeled with CD4 antibody (APC-Cy7) rather than CD4 aptamer for comparison. As shown in ❚Image 2❚, the CD4 aptamer had a nearly identical cell-binding pattern to that for CD4 antibody. Moreover, the CD4 aptamer did not affect staining for CD3, CD8, and CD45 in CD4-expressing Karpas 299 cells (Images 2A-2C ) or CD4-SUDHL-1 cells (Images 2G-2I).
To determine whether the CD4 aptamer may have clinical value, we stained bone marrow cells from healthy donors with the CD4 aptamer along with antibodies for CD8 and CD45. Side scatter and cellular CD45 expression were used to gate marrow cells into different populations, including monocytes, lymphocytes, granulocytes, and nucleated RBCs ❚Image 3A❚. Expression of CD4 and CD8 in each cell population was then analyzed by flow cytometry. As a control, the experiment was repeated with CD4 antibody in place of the CD4 aptamer. We found that the CD4 aptamer and antibody detected very similar patterns of CD4 expression in all cell populations ❚Image 3B❚. Cells from pleural fluid samples of patients with ascites were also stained using CD4 aptamer and antibodies as described above. Flow cytometric analysis of CD4 and CD8 expression showed that the CD4 aptamer and CD4 antibody produced similar staining patterns in CD4+ lymphocytes (green), monocytes (blue), and CD8+ lymphocytes (red) ❚Image 4A❚, ❚Image 4B❚, and ❚Image 4C❚. The distribution of these cell populations was shown according to their side scatter and CD45 expression. Finally, cells from normal lymph nodes were stained using the same sets of aptamer and antibody probes. Cells were then gated into CD4+, CD8+, CD4-/CD8-, and CD4+/CD8+ populations by flow cytometry. We found that the percentage of cells in each population was very similar when CD4 aptamer or CD4 antibody was used ❚Image 4D❚ and ❚Image 4E❚.
Discussion
Since being discovered as a new class of ligand molecules, aptamers have been tested as a probe in a variety of techniques, including the dot plot assay, 12 Western blotting, 13 the enzyme-linked immunosorbent assay, 13, 14 and flow cytometric analysis of cell lines or isolated cells. 10, 11, [15] [16] [17] However, whether the aptamer probes can be used for clinical applications has not yet been explored. In this study, we provide the first evidence that aptamer probes can replace antibodies and be used in combination with antibodies for multicolored cell phenotyping of patient specimens. Compared with antibodies, aptamer probes have unparalleled advantages for clinical use ❚Table 1❚. As small oligonucleotides, aptamers can be generated through simple chemical synthesis, making them easier to produce and more amenable to modifications that are necessary for their use with different reporter systems. In addition, the cost per assay is much less with synthetic aptamer probe than with antibody probes. In this study, we used a customized aptamer, which costs as little as $0.002 per assay. Costs would be expected to be even lower if aptamer probes become commercialized products.
One concern related to the use of RNA-based aptamer probes is their high degree of nuclease susceptibility. However, our study shows that synthetic aptamer probes can be used under routine clinical laboratory conditions without special handling procedures. They are relatively stable in cell-binding buffer containing antibodies and can be used for multicolored cell staining within 24 hours of storage at room temperature. In addition, analysis of the aptamer-stained cells can be delayed for up to 24 hours, but not beyond this time (as seen by an 84.6% reduction in cell staining at 48 hours). These findings indicate that synthetic RNA-based aptamer probes to CD4 are suitable for routine cell phenotyping in clinical laboratories. Our preliminary validation studies have shown that RNA-based aptamer probes to CD30 can specifically detect Hodgkin and anaplastic large cell lymphoma cells in formalin-fixed and paraffin-embedded tissue sections. 18 Whether the same is true of CD4 aptamer remains to be seen. Notably, chemical modifications of synthetic RNA, including sugar modifications (2'-O-Me groups) and/or backbone modifications (phosphorothioate linkages), [19] [20] [21] have been reported to significantly enhance the nuclease resistance of the aptamer probes. Thus, as technology advances and more aptamer probes are discovered, the clinical value of this new class of ligand molecules can be explored further. ❚Image 4❚ Cell phenotyping of patient specimens using the CD4 aptamer. A, B, and C, Pleural fluid cells were stained with antibodies for CD8 and CD45, along with CD4 aptamer or CD4 antibody as a standard control. Flow cytometry identified 3 cell populations based on cellular expression of CD4 and CD8: CD4+ lymphocytes, green; weakly CD4+ monocytes, blue; and CD4-/CD8+ lymphocytes, red. The distribution of cell populations is shown according to side scatter and CD45 expression. D and E, Cells from normal lymph node were also stained with the same sets of aptamer and antibody probes. Subpopulations of cells were then divided according to their CD4 and CD8 expression and quantified by flow cytometry.
